Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Cash Flow (2017 - 2025)

Protagonist Therapeutics' Net Cash Flow history spans 9 years, with the latest figure at $14.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 143.33% year-over-year to $14.7 million; the TTM value through Dec 2025 reached $31.2 million, up 134.87%, while the annual FY2025 figure was $31.2 million, 134.87% up from the prior year.
  • Net Cash Flow for Q4 2025 was $14.7 million at Protagonist Therapeutics, up from -$54.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $183.1 million in Q2 2024 and bottomed at -$224.5 million in Q3 2024.
  • The 5-year median for Net Cash Flow is -$1.5 million (2023), against an average of $553750.0.
  • The largest annual shift saw Net Cash Flow crashed 4524.55% in 2024 before it surged 399.48% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $3.1 million in 2021, then tumbled by 975.43% to -$27.1 million in 2022, then crashed by 61.34% to -$43.8 million in 2023, then grew by 22.67% to -$33.9 million in 2024, then surged by 143.33% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Net Cash Flow are $14.7 million (Q4 2025), -$54.8 million (Q3 2025), and $29.0 million (Q2 2025).